Vanda Pharmaceuticals
VNDA
C$6.44
Share price
-0.43%
Change (1 day)
-22.46%
Change (1 year)
Categories
Vanda Pharmaceuticals (VNDA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : C$0.16 Billion
According to Vanda Pharmaceuticals's latest financial reports the company's total liabilities are C$0.16 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Vanda Pharmaceuticals - Total liabilities on balance sheet (from 2005 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | C$0.16 B | 22.95% |
| 2023-12-31 | C$0.13 B | -5.47% |
| 2022-12-31 | C$0.14 B | 28.26% |
| 2021-12-31 | C$0.11 B | 10.76% |
| 2020-12-31 | C$0.10 B | 7.53% |
| 2019-12-31 | C$95.08 M | 23.09% |
| 2018-12-31 | C$77.24 M | -17.01% |
| 2017-12-31 | C$93.08 M | -12.37% |
| 2016-12-31 | C$0.10 B | -4.31% |
| 2015-12-31 | C$0.11 B | 778.63% |
| 2014-12-31 | C$12.63 M | -88.04% |
| 2013-12-31 | C$0.10 B | -15.39% |
| 2012-12-31 | C$0.12 B | -17.71% |
| 2011-12-31 | C$0.15 B | -13.46% |
| 2010-12-31 | C$0.17 B | -17.8% |
| 2009-12-31 | C$0.21 B | 4381.72% |
| 2008-12-31 | C$4.75 M | -63.68% |
| 2007-12-31 | C$13.1 M | 18.4% |
| 2006-12-31 | C$11.06 M | 86.79% |
| 2005-12-31 | C$5.92 M | 172.68% |
| 2004-12-31 | C$2.17 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | C$84.66 B | 50,920.17% | 🇨🇭 Switzerland |
 Eli Lilly LLY | C$101.25 B | 60,921.08% | 🇺🇸 USA |
 Johnson & Johnson JNJ | C$159.11 B | 95,786.96% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | C$103.23 B | 62,113.43% | 🇺🇸 USA |
 Pfizer PFE | C$161.63 B | 97,304.56% | 🇺🇸 USA |
 Titan Pharmaceuticals
TTNP | C$0.38 M | -99.77% | 🇺🇸 USA |
 Merck MRK | C$91.86 B | 55,262.23% | 🇺🇸 USA |